Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2026 to Discuss Your Rights – INO
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc." or the "Company") (NASDAQ: INO) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inovio Pharmaceuticals, Inc. investors who were adversely affected by alleged securities fraud between October 10, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/inovio-pharmaceuticals-inc-lawsuit-submission-form?prid=183669&wire=3
INO investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Inovio Pharmaceuticals, Inc. during the relevant time frame, you have until April 7, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
